Research Topics
Species | Michael A MorseSummaryAffiliation: Duke University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Fulfilling the promise of immunotherapyCampbell Bunce
Curr Opin Mol Ther 8:9-10. 2006
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccinesMichael A Morse
Department ofMedicine, Duke University Medical Center, Durham, NC 27710, USA
Blood 112:610-8. 2008....
The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pyloriStephen Y Chui
Duke University Medical Center, Box 2606, Durham, NC 27710, USA
Cancer Epidemiol Biomarkers Prev 14:1883-9. 2005..pylori requires an understanding of the complex interactions that make up mucosal immunity. An effective vaccine strategy against H. pylori has the potential to affect significantly on population health worldwide...
Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancerMichael A Morse
Duke University Medical Center, Durham, NC, USA
Expert Opin Biol Ther 9:331-9. 2009..Vaccines for pancreatic cancer have been challenged by a number of factors, especially the immunosuppressive microenvironment within the tumor that allows for escape from immune surveillance...
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory moleculesMichael A Morse
Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 11:3017-24. 2005..To determine the safety and immunologic and clinical efficacy of a dendritic cell vaccine modified to hyperexpress costimulatory molecules and tumor antigen...
Recent developments in therapeutic cancer vaccinesMichael A Morse
Duke University Medical Center, Durham, North Carolina 27710, USA
Nat Clin Pract Oncol 2:108-13. 2005..We will discuss the current state of development of cancer vaccines and the relevance for future clinical use of these agents to treat and prevent cancers...
Virus-based therapies for colon cancerMichael A Morse
Division of Medical Oncology, Duke University Medical Center, Duke South Clinics, Durham, NC 27710, USA
Expert Opin Biol Ther 5:1627-33. 2005..As considerable research has focused on therapy of colon cancer with viral vectors, this review will illustrate the major concepts of viral therapy of cancers with examples from studies targeting colorectal carcinoma...
Current immunotherapeutic strategies in colon cancerMichael Morse
Department of Medicine, Duke University Medical Center, 401 MSRB, Research Drive, Durham, NC 27710, USA
Surg Oncol Clin N Am 16:873-900, x. 2007..The immune system is "programmed" to down-regulate immune responses once they have become activated to avoid the development of autoimmune disease...
Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancerMichael A Morse
Duke University Medical Center, Department of Medicine, Durham, NC 27710, USA
IDrugs 8:974-7. 2005
Technology evaluation: ipilimumab, Medarex/Bristol-Myers SquibbMichael A Morse
Duke University Medical Center, Division of Medical Oncology, Red Zone, Duke South Clinics, Durham, NC 27710, USA
Curr Opin Mol Ther 7:588-97. 2005....
MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancerMichael A Morse
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27410, USA
Clin Cancer Res 17:3408-19. 2011....
Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective studySrinevas K Reddy
Department of Surgery, Duke University Medical Center, Box 3247, Durham, NC 27710, USA
J Gastrointest Surg 13:74-84. 2009..The objective of this retrospective study was to determine the effect of multiagent chemotherapy on long-term survival after resection of CLM...
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivoMichael A Morse
Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Int J Cancer 126:2893-903. 2010..Based on these results, we feel clinical studies using this approach to target HER2-overexpressing breast cancer, including trastuzumab- and lapatinib-resistant tumors is warranted...
Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancerChris R Kelsey
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 69:770-6. 2007..To compare a neoadjuvant regimen of cisplatin/5-fluorouracil (5-FU) and concurrent radiation therapy (RT) with paclitaxel-based regimens and RT in the management of operable esophageal (EC)/gastroesophageal junction (GEJ) cancer...
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2Michael A Morse
Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3233, Durham, NC 27710, USA
J Transl Med 5:42. 2007..We proposed to address these concerns by using cancer vaccines to stimulate HER2 intracellular domain (ICD)-specific T cell and antibody responses...
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patientsTakuya Osada
Duke University Medical Center, Box 3233, Durham, NC 27710, USA
Cancer Immunol Immunother 57:1115-24. 2008..These data suggest that DC differentiation is negatively associated with VEGF levels and may be one explanation for impaired anticancer immunity, especially in patients with advanced malignancies...
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastasesSrinevas K Reddy
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Am Coll Surg 206:96-106. 2008..The objective of this retrospective study was to determine if addition of bevacizumab to iri/oxal preoperative chemotherapy increases morbidity after hepatic resection...
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancerNan Soon Wong
Duke University Medical Center, Durham, NC, USA
Clin Colorectal Cancer 10:210-6. 2011..This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer...
Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysisSrinevas K Reddy
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Ann Surg Oncol 16:1809-19. 2009..However, prospective randomized trials are needed to determine the optimal timing of chemotherapy...
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial resultsBrian G Czito
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 24:656-62. 2006..We initiated two phase I trials assessing the combination of gefitinib, capecitabine, and radiation in patients with localized pancreatic and rectal cancer...
Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapyChris R Kelsey
Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 69:1436-41. 2007..To report patterns of disease recurrence after resection of adenocarcinoma of the duodenum and compare outcomes between patients undergoing surgery only vs. surgery with concurrent chemotherapy and radiation therapy (CT-RT)...
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial resultsBrian G Czito
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 68:472-8. 2007..A Phase I trial was undertaken to evaluate the combination of bevacizumab, capecitabine, oxaliplatin, and radiation therapy in patients with rectal cancer...
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinomaJohn W Nelson
Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC, USA
Int J Radiat Oncol Biol Phys 73:148-53. 2009..To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy...
Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysisAmy C Hobeika
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Immunother (1997) 28:63-72. 2005..These assays will better define the quantity and quality of protective immune responses to viral disease and offer insight into the requirements for protective anti-cancer immunity...
A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tractBrian G Czito
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
Cancer Invest 24:9-17. 2006..We addressed the safety of oral eniluracil/5-FU combined with radiation therapy and determined the profile of dose-limiting toxicities and recommended Phase II dose (RPTD) in patients with pancreatic and hepatobiliary cancers...
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancerNan Soon Wong
Duke University Medical Center, Durham, NC 27710, USA
Anticancer Res 31:255-61. 2011..This study was designed to determine the efficacy and tolerability of capecitabine, oxaliplatin and bevacizumab in combination with cetuximab as first-line therapy for advanced colorectal cancer...
Preparation of peptide-loaded dendritic cells for cancer immunotherapyMichael A Morse
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Mol Biotechnol 25:95-9. 2003..We describe the scheme that we are currently using to generate peptide-loaded dendritic cells for our clinical trials of cancer immunotherapy...
Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinomaA Paiman Ghafoori
Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, North Carolina 27710, USA
Int J Radiat Oncol Biol Phys 81:654-9. 2011..Extrahepatic cholangiocarcinoma is an uncommon but lethal malignancy. We analyzed the role of definitive chemoradiotherapy for patients with nonmetastatic, locally advanced extrahepatic cholangiocarcinoma treated at a single institution...
A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinomaBrian G Czito
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 67:1002-7. 2007..The optimal combination of chemotherapeutic agents with RT is undefined. We evaluated a combination of capecitabine, carboplatin, and paclitaxel with RT in a phase I study...
NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activityTakuya Osada
Duke University Medical Center, Box 3233, Durham, NC 27710, USA
Cancer Immunol Immunother 55:1122-31. 2006..14). Thus, NK responses following DC vaccination may correlate more closely with clinical outcome than do T cell responses. Monitoring of NK response during vaccine studies should be routinely performed...
Investigation of HIFU-induced anti-tumor immunity in a murine tumor modelZhenlin Hu
Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA
J Transl Med 5:34. 2007..This response may play a critical role in a HIFU-elicited anti-tumor immune response which can be harnessed for more effective treatment...
Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experienceBrian G Czito
Department of Radiation Oncology, Duke University Medical Center, Box 3085, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 62:1030-4. 2005..To better define the role of adjuvant radiation therapy and chemotherapy, a retrospective analysis of the outcome of patients undergoing surgery and adjuvant therapy was undertaken...
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumorsElizabeth Dugan
Duke University Medical Center, Durham, North Carolina 27710, USA
Anticancer Res 30:1251-6. 2010..The aim of this study was to determine the maximally tolerated dose, recommended phase II dose and toxicity profile of capecitabine plus imatinib mesylate combination...
Immunotherapy of surgical malignanciesMichael A Morse
Duke University Medical Center, Durham, North Carolina, USA
Curr Probl Surg 41:15-132. 2004
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNAMichael A Morse
Department of Medicine, Medical Center, Box 3233, Durham, North Carolina 27710, USA
Cancer Invest 21:341-9. 2003..We conclude that it is feasible and safe to administer mRNA-loaded DC to patients with advanced malignancies...
Increasing vaccine potency through exosome antigen targetingZachary C Hartman
Duke Comprehensive Cancer Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Vaccine 29:9361-7. 2011..This targeting exosome process could also be adapted for the development of more potent vaccines in some viral and parasitic diseases where the classical vaccine approach has demonstrated limitations...
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancerIvy Altomare
Duke University Medical Center, Durham, North Carolina, USA
Oncologist 16:1131-7. 2011..A phase I study of bevacizumab plus everolimus demonstrated that the combination is safe; activity was seen in several patients with refractory mCRC...
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancerMichael A Morse
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Int J Gastrointest Cancer 32:1-6. 2002..DC-based immunotherapy in this setting is safe and feasible and may lead to prolonged survival...
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)Karen E Bullock
Duke University Medical Center, Seeley G Mudd Bldg, 10 Bryan Searle Drive, Box 3052, Durham, NC 27710, USA
Cancer Chemother Pharmacol 67:465-74. 2011..This study evaluated the safety, tolerability, and pharmacokinetics of bevacizumab, everolimus, and erlotinib combination...
Dendritic cell-based immunotherapyTakuya Osada
Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina 27710, USA
Int Rev Immunol 25:377-413. 2006..In addition, issues regarding the optimal dose and clinical setting for the application of DC vaccines remain to be resolved, and recent clinical studies have been designed to begin to address these questions...
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicityZachary C Hartman
Department of Surgery, Medicine, Division of Medical Oncology, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA
Clin Cancer Res 16:1466-77. 2010..We designed and tested several HER2 vaccines devoid of oncogenic activity to develop a safe vaccine for clinical use...
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancerRebekah R White
Department of Surgery, Duke University Medical Center, Box 3118, Durham, North Carolina 27710, USA
Ann Surg Oncol 12:214-21. 2005..Characterization of the tumor cells that survive neoadjuvant CRT may help us to identify new or more appropriate targets for systemic therapy...
Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplantsMichael A Morse
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
J Hematother Stem Cell Res 11:659-68. 2002....
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapyBenjamin F Johnson
Duke University Medical Center, Duke University School of Medicine, Department of Medicine, Program in Molecular Therapeutics, Comprehensive Cancer Center, Box 2606, Durham, NC 27710, USA
Expert Opin Biol Ther 7:449-60. 2007..Several strategies tested so far have yielded incomplete, yet promising, results...
HER2 dendritic cell vaccinesMichael A Morse
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Clin Breast Cancer 3:S164-72. 2003..The magnitude of the immune responses generated is fairly modest, and more potent DC loading and maturation strategies will be necessary to optimize these vaccines...
Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccineTakuya Osada
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Clin Cancer Res 15:2789-96. 2009....
Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumorsElizabeth Dugan
Duke University Medical Center, Durham, NC, 27710, USA
Anticancer Res 29:5149-53. 2009..To determine the maximally tolerated dose (MTD), recommended phase II dose (RPTD) and toxicity profile of gemcitabine plus irinotecan combination...
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancerMichael A Morse
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
J Clin Invest 120:3234-41. 2010..These data suggest that VRP-based vectors can overcome the presence of neutralizing antibodies to break tolerance to self antigen and may be clinically useful for immunotherapy in the setting of tumor-induced immunosuppression...
Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLsTakuya Osada
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Int Immunol 17:1143-55. 2005..Conversely, the use of NKT cells along with anti-Th2 cytokine-neutralizing antibodies or CD4-negative NKT cell subset could enhance the generation of antigen-specific CTLs for adoptive immunotherapy...
Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCsZhenlin Hu
Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA
Biochem Biophys Res Commun 335:124-31. 2005..The potency in APC activation produced by mechanical lysis is much stronger than thermal necrosis of the tumor cells. These findings suggest that optimization of treatment strategy may help to enhance HIFU-elicited anti-tumor immunity...
Proteomics for monitoring immune responses to cancer vaccinesPaul J Mosca
Department of Surgery, Duke University Medical Center, Box 2606 DUMC, Durtham, NC 27710, USA
Curr Opin Mol Ther 5:39-43. 2003..Advances in miniaturization and automation may also permit characterization of the immune response more rapidly and from smaller amounts of biological material than is possible with existing assay systems...
Depletion of human regulatory T cellsAmy C Hobeika
Departments of Surgery, Duke University Medical Center, Durham, NC, USA
Methods Mol Biol 707:219-31. 2011....
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutationsTakuya Osada
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27705, USA
Cancer Res 71:4172-82. 2011..Our findings support clinical explorations to reposition niclosamide for the treatment of CRC...
Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccinesTimothy M Clay
Duke Comprehensive Cancer Center, Department of Surgery, Duke University Medical Center, 2424 Erwin Road, Suite 601, Durham, NC 27710, USA
Immunol Res 49:235-47. 2011..Further, we will discuss new strategies to augment the clinical efficacy of cancer vaccines by enhancing vaccine immunogenicity and reversing the immunosuppressive tumor microenvironment...
HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesisZachary C Hartman
Duke Comprehensive Cancer Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer Res 71:4380-91. 2011..We suggest that the HER2-IL-6-STAT3 signaling axis we have defined in breast cancer could prompt new therapeutic or prevention strategies for treatment of HER2-amplified cancers...
Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligandPaul J Mosca
Department of General and Thoracic Surgery, Pathology, Immunology, Duke University Medical Center, Durham, North Carolina 27710, USA
J Leukoc Biol 72:546-53. 2002..The ability to generate phenotypically mature, IL-12-producing DC1 from peripheral blood mononuclear cells mobilized by Flt3L will have important implications for the development of effective cancer immunotherapy strategies...
Recent clinical progress in virus-based therapies for cancerChristopher Y Woo
Duke University Medical Center, Department of Medicine, Programme in Molecular Therapeutics, Comprehensive Cancer Center, 401 MSRB, Research Drive, Durham, NC 27710, USA
Expert Opin Biol Ther 6:1123-34. 2006..This review highlights the principles underlying virus-based therapies for cancer, with an emphasis on recent developments from the clinic...
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancerNan Soon Wong
Duke University Medical Center, Durham, North Carolina, USA
Cancer Invest 29:617-25. 2011..Two patients had partial response; seven patients had stable disease at least 6 months. Oral lonafarnib at 150 mg a.m./100 mg p.m. plus gemcitabine at 1,000 mg/m(2) is the maximum tolerated dose with acceptable safety and tolerability...
Immune monitoringPaul J Mosca
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Cancer Treat Res 123:369-88. 2005..It should be the goal and expectation that this rational approach to immune monitoring will allow the critical appraisal of the most promising vaccine candidates in the context of pivotal, multi-center trials...
Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patientsMichael A Morse
Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 17:4844-53. 2011..We wished to test whether targeted delivery of an otherwise poorly immunogenic, soluble antigen to APC through their mannose receptors (MR) would induce clinically relevant immunity...
Assessing the quality of colorectal cancer care: do we have appropriate quality measures? (A systematic review of literature)Meenal Patwardhan
Department of Medicine, Duke University Medical Center, Durham, NC, USA
J Eval Clin Pract 13:831-45. 2007..We also evaluated the extent to which these measures are ready to be implemented in clinical practice, and identified areas for future research...
A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colonBrian G Czito
Department ofRadiation Oncology, Duke University Medical Center, Durham, NC, USA
Int J Radiat Oncol Biol Phys 58:779-85. 2004..One patient had a pathologic complete response. CONCLUSION: Preoperative chemoradiotherapy with oral eniluracil and 5-FU is feasible and well tolerated. Additional investigation is warranted...
Gene therapy for lung cancerEric M Toloza
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
J Cell Biochem 99:1-22. 2006..This article will discuss the therapeutic implications of these molecular changes associated with bronchogenic carcinomas and will then review the status of gene therapies for treatment of lung cancer...
Current status of dendritic cell immunotherapy of malignanciesPaul J Mosca
Departments of Surgery and Medicine, Duke University Medical Center, Durham, North Carolina, USA
Int Rev Immunol 22:255-81. 2003..Clinical responses such as stability of disease and tumor regressions have been reported in some patients, particularly with melanoma, myeloma, and prostate cancer...
Recent areas of development for dendritic cell vaccinesMichael A Morse
Duke University Medical Center, Durham, NC 27710, USA
Cancer Chemother Biol Response Modif 21:339-50. 2003
Immunotherapeutic targeting of Wilms' tumor proteinYalonda Hutchings
Duke University Medical Center, Departments of Medicine and Surgery, 401 MSRB, Research Drive, Durham, NC 27710, USA
Curr Opin Mol Ther 9:62-9. 2007..Because peptide-based vaccines are human leukocyte antigen-restricted, other more broadly applicable strategies are now being developed to activate WT1-specific immune responses, including the use of WT1-specific viral vectors...
Immunoregulatory T cells in cancer immunotherapyMichael A Morse
Department of Medicine, Duke University Medical Center, Box 3233, Durham, NC 27710, USA
Expert Opin Biol Ther 2:827-34. 2002..One hypothesis is that depleting these CD4+CD25+ counter-regulatory T cells in humans with cancer will enhance the efficacy of anticancer immunisations...
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expressionKatherine M Aird
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Mol Cancer Ther 7:38-47. 2008..These data have identified a novel functional link between ErbB2 signaling and antiapoptotic pathway mediated by XIAP. Blockade of the IAP antiapoptotic pathway alone or in combination would be an attractive strategy in IBC therapy...
CEA loaded dendritic cell vaccinesMichael A Morse
Departments of Medicine and Surgery, Duke University Medical Center, P.O. Box 3233, Durham, NC 27710, USA
Cancer Chemother Biol Response Modif 20:385-90. 2002
Combining cancer vaccines with chemotherapyGabriel Chong
Division of Medical Oncology, Duke South Clinics, Duke University Medical Center, Durham, NC 27710, USA
Expert Opin Pharmacother 6:2813-20. 2005..As such, more preclinical and clinical trials are needed to explore the synergistic effects of chemotherapy combined with immunotherapy, particularly the proper dose and timing of chemotherapy...
Dendritic cell vaccinesPaul J Mosca
Duke Comprehensive Cancer Center Duke University Medical Center, Durham, NC 27710, USA
Front Biosci 12:4050-60. 2007..The emphasis of dendritic cell immunotherapy research is increasingly shifting toward the development of strategies to increase the potency of dendritic cell vaccine preparations...
DNA and RNA modified dendritic cell vaccinesMichael A Morse
Department of Medicine, Duke University Medical Center, Box 2606, Durham, North Carolina 27710, USA
World J Surg 26:819-25. 2002..Genetic modification can be effected by either DNA or RNA, and the genetic material may be delivered by vectors or by physical means. These approaches are now entering human clinical trials...
Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic reviewRobert G Prosnitz
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer 107:2352-60. 2006..Therefore, the authors conducted a systematic review of the literature to determine the available QMs for adjuvant CT and RT in patients with CRC and rated their usefulness for assessing the delivery of quality care...
Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical centerNicole L Hansen
Department of Pharmacy, Duke University Medical Center, Durham, NC 27710, USA
J Oncol Pharm Pract 17:125-30. 2011....
Current status of adoptive immunotherapy of malignanciesMichael A Morse
Department of Medicine and Surgery, Duke University Medical Center, MSRB Room 401, Box 3233, Durham, NC 27710, USA
Expert Opin Biol Ther 2:237-47. 2002..In addition to work being done to develop the most potent effector, other studies are working on improving T-cell trafficking to tumours and interfering with the tumour-induced immunosuppression that can impair in vivo T-cell activity...
CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancerMichael A Morse
Duke University Medical Center, 10 Bryan Searle Drive, 477 Seeley G Mudd Building, Durham, NC 27710, USA
Expert Rev Vaccines 10:733-42. 2011..An ongoing Phase II trial evaluates CDX-1307 in patients with newly diagnosed, resectable, hCG-?-expressing bladder cancer, where low tumor burden and early intervention may provide greater potential for benefit...
Cryosurgery after chemoembolization for hepatocellular carcinoma in patients with cirrhosisPierre Alain Clavien
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Duke University Medical Center, Durham, NC, USA
J Gastrointest Surg 6:95-101. 2002..TACE may reduce the risk of hemorrhage after cryosurgery but can increase the risk of hepatic failure in patients with poor hepatic function...
Pharmacological inhibition of TGF? as a strategy to augment the antitumor immune responseBrent A Hanks
Department of Internal Medicine, Division of Hematology and Oncology, Duke University Medical Center, 450 Research Drive, Durham, NC 27708, USA
Curr Opin Investig Drugs 11:1342-53. 2010....
A year of successful cancer vaccines points to a path forwardMichael A Morse
Duke University Medical Center, Durham, NC 27710, USA
Curr Opin Mol Ther 12:11-3. 2010..These data support the further development of such vaccines, and provide guidance for the development of improved agents and protocols for the use of therapeutic vaccination to treat cancer...
Dendritic cell maturation in active immunotherapy strategiesMichael A Morse
Department of Mecine and Surgery, Duke University Medical Center, Durham, NC 27710, USA
Expert Opin Biol Ther 2:35-43. 2002....
Adenovirus vaccine immunotherapy targeting WT1-expressing tumorsJeffrey M Clarke
Department of Medicine, Duke University Medical Center, DUMC Box 31379, Durham, NC 27710, USA
Expert Opin Biol Ther 10:875-83. 2010..Wilm's Tumor gene (WT1) is a robust TAA which is overexpressed in many malignancies and has been recently used to develop a novel recombinant adenovirus (Ad-WT1) for antitumor immunotherapy...
CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapyYanal M Murad
Duke University Medical Center, Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, Durham, NC 27710, USA
Expert Opin Biol Ther 7:1257-66. 2007..Phase I and II trials have tested this drug in several hematopoietic and solid tumors. Pfizer has initiated Phase III trials to test PF-3512676 in combination with standard chemotherapy for non-small-cell lung cancer...
Successful desensitization to oxaliplatinLydia Mis
Department of Pharmacy, Duke University Medical Center, Durham, NC 27710 3089, USA
Ann Pharmacother 39:966-9. 2005..To report the successful desensitization of a patient to oxaliplatin utilizing an 8-hour desensitization regimen in a controlled environment...
Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysisSrinevas K Reddy
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Ann Surg Oncol 14:3481-91. 2007..This multi-institutional retrospective study compared postoperative outcomes after simultaneous and staged colorectal and hepatic resections...
Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysisSrinevas K Reddy
Department of Surgery, Duke University Medical Center, Durham, NC 27713, USA
J Am Coll Surg 204:372-82. 2007..Although established for metastatic colorectal (CR) and neuroendocrine (NE) malignancies, the role of partial hepatectomy in management of metastases from other primaries (NCRNE) is not well-defined...
Role of natural killer cell function in dendritic cell-based vaccinesChristopher Y Woo
Program in Molecular Therapeutics, Comprehensive Cancer Center, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Expert Rev Vaccines 5:55-65. 2006..In this article, the authors will review studies focusing on NK-DC interactions and highlight the most recent clinical findings relating to the potential role of NK cells in DC-based vaccine therapy...
De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplantMichael A Heneghan
Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
Am J Transplant 3:634-8. 2003..No viable tumor was identified in the explanted liver. This case establishes that long-term complications associated with PSC and biliary-enteric surgery such as CCA may become apparent in new grafts post-transplant...
Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenesTimothy M Clay
Duke University Medical Center, Program in Molecular Therapeutics, Department of Surgery, Durham NC 27710, USA
Expert Opin Biol Ther 2:353-60. 2002....
Technology evaluation: Rexin-G, Epeius BiotechnologiesMichael Morse
Duke University Medical Center, Division of Medical Oncology, Box 3233 Room 3803, Red Zone, Duke South Clinics, Durham, NC 27710, USA
Curr Opin Mol Ther 7:164-9. 2005..The therapy is currently undergoing phase I/II clinical trials...
A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinomaEmil Lou
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Clin Colorectal Cancer 5:368-71. 2006
Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapyPierre-Alain Clavien
Department of Surgery, Division of Hematology and Oncology, Duke University Medical Center, Durham, NC, USA
Surgery 131:433-42. 2002..This strategy appears particularly promising in patients with large HCC. This approach should be investigated further...
Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cellsSmita K Nair
Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, North Carolina 27710, USA
Ann Surg 235:540-9. 2002..CONCLUSIONS: DCs transfected with total tumor RNA may represent a method for inducing immune responses against the entire repertoire of tumor antigens of surgically resected malignancies...
Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNACarlos Micames
Duke University Medical Center, Department of Medicine, Durham, North Carolina 27710, USA
Gastrointest Endosc 58:690-5. 2003..A concern for peritoneal seeding of pancreatic cancer via percutaneous FNA is warranted. EUS-guided FNA is recommended as the method of choice for diagnosis in patients with potentially resectable pancreatic cancer...
Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastasesMark Onaitis
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Ann Surg 237:782-8; discussion 788-9. 2003..This fact, in light of the potential toxicity, would argue for a larger confirmatory trial of HAI in the adjuvant setting, incorporating recent advances in systemic therapy and careful attention to hepatotoxicity...
Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppressionBenjamin Johnson
Duke University Medical Center, MSRB Room 433, Box 3233, Durham, NC 27710, USA
Curr Mol Med 9:702-7. 2009..Therapies intended to inhibit VEGF or VEGF receptors have demonstrated improved anti-tumor immunity and enhanced responses to cancer vaccines...
Update on anti-CTLA-4 antibodies in clinical trialsLee F Langer
Duke University Medical Center, Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, Durham, NC 27710, USA
Expert Opin Biol Ther 7:1245-56. 2007..This article reviews preclinical development and data generated from Phase I, II and III studies with regard to the end points reported and immune-related adverse events...
The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumorsPeter E Fecci
Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
J Neurooncol 64:161-76. 2003..The future success of clinical trials will depend on the optimization and standardizing of procedures for DC generation, loading, and administration...
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptidesHolden T Maecker
BD Biosciences, San Jose, CA, USA
BMC Immunol 9:9. 2008..Here we assess the levels of intra-assay, inter-assay, and inter-operator precision, as well as linearity, of CD8+ T cell IFNgamma-based ELISPOT and cytokine flow cytometry (CFC), as well as tetramer assays...
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOTHolden T Maecker
BD Biosciences, San Jose, USA
BMC Immunol 6:17. 2005..In this study, we compared the performance of these assays on leukapheresed PBMC shipped overnight in medium versus cryopreserved PBMC from matched donors...
Toward protecting the safety of participants in clinical trialsRobert M Califf
Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
Control Clin Trials 24:256-71. 2003..DMC composition and functions should be standardized and regulations should be harmonized nationally and internationally. Finally, there should be a concerted effort to study the efficacy of various components of the system...
A need for effective adjuvantsCampbell J Bunce
Curr Opin Mol Ther 5:8-9. 2003
